Figure S5 from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
Year: 2023
Type: other
Abstract: ADI-PEG20 efficacy in an extended panel of ovarian cancer cell lines. Cells were treated with 0.63 µg/mL ADI-PEG20. First row represents ASS1 expressing cell lines, whereas the rest of the cells are ASS1 deficient, therefore sensitive to ADI-PEG20 treatment. OVCAR3: HGSC cell line; JHOC 9, OVTOKO: CCOC cell lines. BIN67, SCCOHT1: SCCOHT cell lines; OVISE and ES2 represent atypical CCOC/ENOC based on molecular characterizations; TOV112D: de-differentiated ovarian cancer cell line. Error bars represent standard error of mean.
Authors: Jennifer X. Ji, Dawn R. Cochrane, Basile Tessier-Cloutier, Shary Yutin Chen, Germain Ho, Khyatiben V. Pathak, Isabel N. Alcazar, David Farnell, Samuel Leung, Angela Cheng, Christine Chow, Shane Colborne, Gian Luca Negri, Friedrich Kommoss, Anthony Karnezis, Gregg B. Morin, Jessica N. McAlpine, C. Blake Gilks, Bernard E. Weissman, Jeffrey M. Trent, Lynn Hoang, Patrick Pirrotte, Yemin Wang, David G. Huntsman
Language: English
Subfield: Biotechnology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361889143